Data from a physician- sponsored clinical trial designed to compare the efficacy of Xibrom™(bromfenac ophthalmic solution) 0.09% with two topical non-steroidal anti- inflammatory solutions (NSAIDs) that were given four times a day for the treatment of acute pseudophakic cystoid macular edema(CME) showed that twice-daily dosing of Xibrom™ is equally effective.
Xibrom™ from ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA) is a topical, twice-daily NSAID approved by the USFDA for the treatment of ocular inflammation and reduction of pain following cataract surgery.’
The clinical trial data were presented in a poster session during the 2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in
Source: Ista Vision News
Comment Preview